Minimal residual disease in hematologic disorders.
In almost no other area of medical oncology has the introduction of new drugs, combinations of chemotherapeutic agents, and novel biologic treatments caused such dramatic responses as it has in the treatment of malignant hematologic disorders. However, despite some therapeutic success, many patients relapse and die from recurrence of their disease. The implications of minimal residual disease (MRD), a term referring to disease that is undetectable by conventional morphologic methods, have therefore attracted increasing attention in recent years. New and powerful laboratory tools such as polymerase chain reaction assays have extraordinary sensitivity and provide exciting new insights into the detection, nature, quantification, and kinetics of MRD. This article summarizes methods used in the identification of MRD and its importance as exemplified in the case of acute leukemias and chronic myelogenous leukemia.
Faderl
S
S
Department of Bioimmunotheraphy, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Kurzrock
R
R
Estrov
Z
Z
D000328:Adult; D002648:Child; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000235:genetics* / Q000473:pathology; D006801:Humans; D016130:Immunophenotyping; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D007938:Leukemia / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D016133:Polymerase Chain Reaction; D012008:Recurrence; D014410:Tumor Stem Cell Assay